Background-Several cases of unexpected death have been reported with sildenafil in patients predisposed to ischemic cardiac events. Although acute episodes of ischemia could account for some of these deaths, we hypothesized that sildenafil may have unsuspected electrophysiological effects predisposing some patients to proarrhythmia. Methods and Results-Studies were undertaken in 10 isolated guinea pig hearts that demonstrated prolongation of cardiac repolarization in a reverse use-dependent manner by sildenafil 30 mol/L. Action potential duration increased 15% from baseline 117Ϯ3 to 134Ϯ2 ms with sildenafil during pacing at 250 ms cycle length, whereas a 6% increase from 99Ϯ2 to 105Ϯ2 ms was seen with pacing at 150 ms cycle length. Experiments in human ether-a-go-go-related gene (HERG)-transfected HEK293 cells (nϭ30) demonstrated concentration-dependent block of the rapid component (I Kr ) of the delayed rectifier potassium current: activating current was 50% decreased at 100 mol/L. This effect was confirmed using HERG-transfected Chinese hamster ovary (CHO) cells, which exhibit no endogenous I K -like current. Conclusions-Sildenafil possesses direct cardiac electrophysiological effects similar to class III antiarrhythmic drugs.
T he drug sildenafil citrate is a successful tool in the treatment of impotence through a selective inhibition of the phosphodiesterase V that inactivates cyclic guanine monophosphate (cGMP), the mediator of smooth muscle relaxation in the corpus cavernosum. 1, 2 As impotence is a common problem among patients with cardiac disease, sildenafil is increasingly prescribed by cardiologists. 3 Several deaths have been reported in patients taking sildenafil, but it was generally assumed that they were related to an underlying disease (eg, ischemia) and not to a specific drug effect. 3, 4 We investigated whether unexpected electrophysiological effects of sildenafil on cardiac repolarization might provide an alternate explanation for an increased risk of sudden death. We therefore determined action potentialprolonging effects of sildenafil in isolated hearts and characterized the effects of the drug on I Kr using the patch-clamp technique.
Methods
Experiments were performed in accordance with our institutional guidelines on animal use in research. Animals were housed and maintained in compliance with the Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care.
Experiments With Isolated Hearts
Experiments with isolated guinea pig hearts were performed as described previously. 5 The hearts were perfused with KrebsHenseleit buffer during a control period of 10 minutes, followed by 15 minutes with buffer containing 30 mol/L of sildenafil dissolved in 100 L of dimethylsulfoxide (DMSO). Perfusion with buffer containing no drug was then restarted during a 10-minute washout period. Monophasic action potentials from the left ventricle were recorded every 60 seconds for brief periods of 3 seconds, at basic pacing cycle lengths (BCL) of 250, 200, and 150 ms.
Patch-Clamp Experiments
Experiments were performed on human ether-a-go-go-related gene (HERG)-transfected HEK293 cells. Preparation and harvesting of the HEK293 cells were done as described by Zhou et al. 6 Membrane currents were recorded in whole cell configuration using suction pipettes. The composition of superfusion and internal pipette solutions were described by Zhou et al. 6 Sildenafil solutions of 1 to 100 mol/L were prepared daily by dissolving required amounts of the drug in 100 L of DMSO. The same volume of DMSO was added in baseline and washout buffer solutions. HERG gene was also transiently transfected in CHO cells as described by Bérubé et al. 7 Recordings of currents and composition of superfusion and internal pipette solutions were described by Bérubé et al. 7 All voltage-clamp experiments were performed at 22°C to 23°C.
Statistical Analysis
Data are presented as meansϮSEM. Isolated heart data on the magnitude of sildenafil effects were analyzed with a student's paired t test. In the patch-clamp experiments, concentration-dependent block of HERG activating current was tested by Hotelling's T 2 test. A P value Ͻ0.05 was considered statistically significant.
Results

Experiments With Isolated Hearts
Examples of monophasic action potentials recorded at baseline and during perfusion with sildenafil 30 mol/L at a BCL of 250 ms are illustrated in Figure 1A . Experiments in isolated hearts (nϭ10) showed an increase in monophasic action potential duration measured at 90% repolarization (MAPD 90 ) during perfusion with sildenafil 30 mol/L ( Figure  1B ): At a BCL of 250 ms, MAPD 90 increased from 117Ϯ3 ms at baseline to 134Ϯ2 ms after 15 minutes of drug perfusion (PϽ0.05), decreasing back to 126Ϯ4 ms after 10 minutes of washout (PϽ0.05 versus sildenafil). At the shortest BCL of 150 ms, MAPD 90 increased from 99Ϯ2 at baseline to 105Ϯ2 ms after sildenafil perfusion (PϽ0.05), returning to baseline after washout (99Ϯ2 ms). Thus, sildenafil was associated with a 15% increase in MAPD 90 at the longest BCL and with a 6% increase at the shortest BCL. Such reverse usedependent characteristics are typically seen with I Kr blockers.
Patch-Clamp Experiments
The mechanism of the action potential-prolonging effect of sildenafil was elucidated by the patch-clamp experiments in HEK293 and in CHO cells. Figure 2A shows currents elicited in a HERG-transfected HEK293 cell perfused under control conditions, after 15 minutes of sildenafil 30 mol/L and after 20 minutes of washout. In this cell, sildenafil 30 mol/L caused a Ϸ40% reduction of the activating current, whereas the reduction of the tail current was Ϸ25%.
To ascertain that the effects of sildenafil were not due to a modulation of a HEK293 cell endogenous current, we confirmed the inhibitory effects of sildenafil in HERGtransfected CHO cells, which exhibit no I K -like endogenous currents. 8 Figure 2B shows currents elicited in a HERGtransfected CHO cell perfused under control conditions, after 15 minutes of sildenafil 30 mol/L and after 20 minutes of washout. In this cell, sildenafil 30 mol/L caused a Ϸ50% reduction of the activating current, and a Ϸ44% reduction of the tail current. Sildenafil 30 mol/L had no effect on HERG channel activation, deactivation, or inactivation kinetics.
In HERG-transfected HEK293 cells, block of activating currents was assessed with sildenafil concentrations ranging from 1 to 100 mol/L and the data were fitted to the Hill equation, giving an estimated IC 50 of 100 mol/L ( Figure 2C ).
Discussion
Our results indicate that sildenafil can prolong cardiac repolarization by blocking I Kr . In fact, we have shown that sildenafil 30 mol/L caused a clinically relevant 15% prolongation of cardiac repolarization, which is comparable with the effect of cisapride 100 nmol/L under the same conditions. 5 It has been shown that I Kr block may lead to triggered ventricular arrhythmias and sudden death. 9 These results provide a new potential explanation for sudden death during sildenafil treatment.
Inhibition of HERG current was demonstrated in both HEK293 and CHO cell lines. In HEK293 cells, the estimated IC 50 for I Kr was 100 mol/L. Plasma concentrations of sildenafil after treatment with single doses of 25 to 100 mg are around 1 mol/L. 10 Because sildenafil is a strong lipophilic drug, relevant tissue concentrations are probably higher. However, based on our results, several-fold higher plasma concentrations than these encountered in clinical practice would be required before significant I Kr block occurred. Drug metabolism studies have demonstrated that CYP3As are the principal enzymes involved in the biotransformation of sildenafil. 10 Thus, one could expect an important rise in sildenafil plasma levels when it is coadministered with CYP3A inhibitors (macrolides, imidazoles) or other CYP3A substrates (many cardiac drugs, such as calcium antagonists and statins). Indeed, a 20-fold increase in cisapride plasma concentrations (another inadvertent I Kr blocker that is a CYP3A4 substrate) was reported during coadministation with fluconazole and erythromycin. 11 The cardiovascular effects of sildenafil in randomized, controlled clinical trials were minor, although patients with underlying heart disease were generally excluded from these studies. 1, 10, 12 From April 1998 through mid-November 1998, the FDA has been able to document 130 cases of death in US patients using sildenafil. Sixty-two percent of them died of cardiovascular events (mostly myocardial infarction or cardiac arrest), whereas the cause of death was unmentioned or unknown for 37% of patients. 10 Therefore, care should be taken when prescribing sildenafil to patients with cardiac disease. 4 Care should also be taken with patients at risk for impaired drug elimination and is further emphasized by these new findings. Because sildenafil can block I Kr , caution is also needed during coadministration with other I Kr blockers such as class III drugs and other compounds such as erythromycin, antihistamines, and cisapride. 5, 13, 14 Moreover, the present findings with sildenafil should also remind the whole concern of acquired long QT syndrome as a "drug-revealed" form of silent congenital long QT syndrome, observable under the effect of a growing list of drugs.
Conclusions
Sildenafil blocks I Kr and prolongs cardiac repolarization at concentrations that may be seen after drug overdose or in the presence of impaired drug elimination. Clinical attention to QT prolongation and triggered ventricular tachyarrhythmias is warranted in patients with hepatic or renal insufficiency or suffering from the long QT syndrome and in patients on multi-drug regimens.
